Pharmaceuticals | Bayer | Bayer Global
As a leading healthcare company, Bayer offers innovative solutions for the prevention, alleviation and treatment of diseases. Bayer's Pharmaceuticals Division focuses on prescription products for women's health, cardiology, oncology, hematology and ophthalmology.
Bayer - Wikipedia
Bayer AG (English: / ˈ b aɪ. ər /, commonly pronounced / ˈ b eɪ ər /; [3] German:) is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world.
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline …
6 days ago · San Francisco, CA, USA, January 14, 2025 – On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy, with multiple filing submissions underway for key growth drivers darolutamide and finerenone, acoramidis and elinzanetant. “We are successfully delivering on our ambitious business goals despite ...
Bayer – Global Home
At Bayer, we believe it´s possible to create a better world where health and nutrition are accessible to all, embodying our mission "Health for all, Hunger for none". As a global company with core competencies in health care and agriculture, we design our products and services to address the world´s greatest challenges and the most ...
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline …
5 days ago · WHIPPANY, N.J., January 14, 2025--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with ...
Pharmaceutical Brands | Bayer United States
Our pharmaceutical brands are just one of the many ways we seek to enable better health for people and patients across various ailments. Find our current list of offerings in the U.S. below. Adempas® (ricoigaut)
Vividion Therapeutics Acquires Tavros Therapeutics to Expand ... - Bayer
5 days ago · “The acquisition of Tavros is an exciting next step as we seek to accelerate the development of previously undruggable targets to improve outcomes for patients with significant high unmet medical needs”, said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division.
Bayer’s Pharma Growth Strategy Progressing Well as ... - BioSpace
5 days ago · Through rigorous assessment and prioritization, Bayer Pharmaceuticals is now fully focused on the areas of greatest unmet need and highest value potential. Targeted investments in R&D and platform companies in recent years are already strengthening Bayer’s early and late pipelines. With Vividion´s acquisition of the precision oncology ...
JPM25: Bayer readies for 'must-win battles' - fiercepharma.com
4 days ago · Bayer's pharma chief counts potential launches of the ATTR-CM drug acoramidis and the menopause med elinzanetant among “must-win battles” at the company. Although Bayer’s top-selling drug ...
Bayer HealthCare Pharmaceuticals - Drugs.com
Aug 22, 2024 · Bayer HealthCare Pharmaceuticals Inc. manufactures, markets and/or distributes more than 23 drugs in the United States. Medications listed here may also be marketed under different names in different countries.
- Some results have been removed